Investigating safety, tolerability and pharmakinetics when giving single and fractionated doses of AZD3241 to healthy volunteers - SAD

Study identifier:D0490C00012

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Single-centre, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD3241 following Administration of Single Ascending (Part A) and Fractionated Ascending (Part B) Oral Doses to Young Healthy Volunteers

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3241, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 49 Years

Date

Study Start Date: 01 Jul 2008

Primary Completion Date: 01 Nov 2008

Study Completion Date: 01 Nov 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2008 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Stockholm, Sweden

Arms	Assigned Interventions
Experimental: 1	Drug: AZD3241 single oral dose
Placebo Comparator: 2	-

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Ingemar Bylesjö

Astrazeneca Clinical Pharmacology Unit, Stockholm, Sweden